ClinicalTrials HQ

Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML

Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML

Active, not recruiting · NCT02091245 · Registry updated 2026-05-29
Ask about research services

Clinical trials

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AMLChronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myeloproliferative Disorders, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, acute myeloid leukemia, bone marrow disorder, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, myeloid leukemia, neoplasmActive, not recruitingPhase 12026-05-29NCT02091245

3 results · Page 1 of 1

Organizations

Swipe the table sideways for more columns.

OrganizationsLinked trials
Dana-Farber Cancer Institute324
Karyopharm Therapeutics Inc25
William Lawrence and Blanche Hughes Foundation1

10 results · Page 1 of 1

Research sites

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Boston Children's HospitalBostonUnited States343
Children's Healthcare of AtlantaAtlantaUnited States47
Children's Hospital ColoradoAuroraUnited States312
Children's Hospital of PhiladelphiaPhiladelphiaUnited States434
Children's Hospital of WisconsinMilwaukeeUnited States87
Columbia University Medical centerNew YorkUnited States224
Dana-Farber Cancer InstituteBostonUnited States626
Seattle Children's HospitalSeattleUnited States8
Texas Children's HospitalHoustonUnited States187
UCSFSan FranciscoUnited States27